- Home
- ARBK vs ATHA Comparison
ARBK vs ATHA Comparison
Compare ARBK & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARBK | ATHA |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 18.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARBK | ATHA |
|---|---|---|
| Price | $0.21 | $4.20 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 26.9K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,043,000.00 | N/A |
| Revenue This Year | $183.90 | N/A |
| Revenue Next Year | $26.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $2.20 |
| 52 Week High | $1.12 | $6.68 |
Technical Indicators
Market Signals| Indicator | ARBK | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 47.33 |
| Support Level | $0.20 | $4.31 |
| Resistance Level | $0.27 | $4.74 |
| Average True Range (ATR) | 0.03 | 0.35 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 9.26 | 19.59 |
Price Performance
Historical ComparisonAbout ARBK Argo Blockchain plc
Argo Blockchain PLC is a blockchain technology company focused on the large-scale mining of Bitcoin. It mines bitcoin using purpose-built computers (or mining machines) to solve complex cryptographic algorithms on the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company acquires and deploys mining technology solutions in North American facilities that utilize predominantly renewable and inexpensive electricity.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.